Cat. No. | Product name | CAS No. |
DC7363 |
AT-406
Featured
AT-406 (formerly known as SM-406) is an orally bioavailable potent IAP (inhibitor of apoptosis protein) of XIAP, cIAP1, and cIAP2 with Ki of 66.4 nM, 1.9 nM, and 5.1 nM, respectively. |
1071992-57-8 |
DC23554 |
AT791
AT791 is a novel orally available, small molecule inhibitor of TLR7 and TLR9 with IC50 of 3.33 uM and 0.04 uM respectively, inhibits DNA-TLR9 interaction in vitro. |
1219962-49-8 |
DC21122 |
Ataciguat sodium
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
254976-06-2 |
DC21121 |
Ataciguat
Featured
Ataciguat (HMR-1766) is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.51 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC. |
254877-67-3 |
DC23606 |
Atagabalin
Atagabalin (PD 0200390) is a novel ligand of the voltage-dependent calcium channel (VDCC) α2δ subunit (1 and 2) for treatment for insomnia.. |
223445-75-8 |
DC7365 |
ATB-346
Featured
ATB-346 is a novel hydrogen sulphide-releasing derivative of naproxen with markedly reduced toxicity. |
1226895-20-0 |
DC7366 |
Atglistatin
Featured
Atglistatin is a highly potent, selective and competitive inhibitor of adipose triglyceride lipase (ATGL) with an IC50 of ~0.7 μM for inhibition of lipolysis in vitro, but no toxicity up to a concentration of 50 μM. |
1469924-27-3 |
DC21656 |
Atiprimod
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
123018-47-3 |
DC21657 |
Atiprimod dihydrochloride
Atiprimod (SKF 106615, Azaspirane) is a potent, orally bioavailable JAK2 inhibitor, inhibits phosphorylation of JAK2 and the downstream STAT3 and STAT5 pathways. |
130065-61-1 |
DC20033 |
ATM Inhibitor-1
ATM Inhibitor-1 is a highly potent, selective and orally active ATM inhibitor, with an IC50 of 0.7 nM, shows weak activity against mTOR (IC50, 21 μM), DNAPK (IC50, 2.8 μM), PI3Kα (IC50, 3.8 μM), PI3Kβ (IC50, 10.3 μM), PI3Kγ (IC50, 3 μM) and PI3Kδ (IC50, 0 |
2135639-94-8 |
DC12627 |
ATM-3507
ATM-3507 (ATM3507) is a small molecule inhibitor of Tpm3.1 tropomyosin isoform, disrupts Tpm3.1-containing microfilaments in SK-N-SH cells at 5 uM. |
1861449-70-8 |
DC7709 |
ATN-161
Featured
ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. |
262438-43-7 |
DCAPI1522 |
Atocalcitol
Atocalcitol |
302904-82-1 |
DC23607 |
Atomoxetine
Atomoxetine ((R)-Tomoxetine. |
83015-26-3 |
DCAPI1390 |
Atovaquone (Atavaquone)
Featured
Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. |
95233-18-4 |
DCAPI1401 |
ATP (Adenosine-Triphosphate)
ATP (Adenosine-Triphosphate) |
987-65-5 |
DC11095 |
ATR-101 free base
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
133825-80-6 |
DC22775 |
ATR-101
ATR-101 (PD-132301, Nevanimibe) is a selective and potent inhibitor of ACAT1 with IC50 of 52 nM. |
133825-81-7 |
DC23072 |
Atractylenolide II
Featured
Atractylenolide II has antiinflammatory activity, it can inhibit platelets activities and thrombus formation. Atractylenolide II has cytotoxic/apoptotic effects may via p38 activation ,ERK and Akt inactivation, p53 dependent, it also has antimelanoma effe |
73069-14-4 |
DC23073 |
Atractylenolide III
Featured
Atractylenolide III, a potential house dust mite control agent, has neuroprotection, gastroprotective, anti-cancer, and anti-inflammatory activities, it also may control immunological reactions by regulating the cellular functions of IL-6 in mast cells. |
73030-71-4 |
DC23059 |
Atractylon
Featured
Atractylone has inhibitory effects on mast cell-mediated allergic reactions, it regulates the degranulation of mast cell, proves its potential in the treatment of mast cell-mediated allergic reactions. |
6989-21-5 |
DCAPI1288 |
Atracurium besylate
Featured
Atracurium besylate is a non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents. |
64228-81-5 |